Who are we ?

Genexpath is a company specialized in in vitro molecular diagnostics, created in Rouen from cutting-edge technology developed within the INSERM U1245 laboratory at the Henri Becquerel Center, led by Professor Fabrice Jardin. The company designs, produces, and markets innovative biomolecular tests and panels for the characterization of pathologies, particularly B- and T-cell lymphomas as well as sarcomas.

Our Mission

Our goal is to provide high-precision molecular biology and bioinformatics tools to improve disease understanding, enhance diagnostics, and accelerate patient care. Our solutions cover the full workflow — from bench to bioinformatics analysis — with a strong commitment to making innovation accessible to researchers, clinicians, and healthcare institutions.

Part of the CliniSciences Group

Since July 2025, Genexpath has been part of the CliniSciences Group, a major European player in the distribution and development of solutions for research and diagnostics. This integration strengthens our expertise in hemato-oncology and molecular diagnostics, while broadening our clinically relevant product offering.

Location, Team & Quality Commitment

All production, quality control, and software development activities are carried out at our facilities in Rouen, Normandy. Our multidisciplinary team includes scientists, bioinformaticians, and experts in diagnostic test development, all dedicated to providing outstanding service to our users.

Genexpath is ISO 13485: 2016 certified, ensuring compliance with the highest standards for the design, production, and distribution of in vitro diagnostic medical devices.